SCHEDULE: Aura Biosciences: Suvretta Group Boosts Stake

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen disclose increased beneficial ownership in Aura Biosciences, Inc., reaching up to 7.6% of common stock.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an Amendment No. 1 to their Schedule 13G for Aura Biosciences, Inc.
• A collective beneficial ownership of 4,701,775 shares of Aura Biosciences' Common Stock is reported by Suvretta Capital Management, LLC and Aaron Cowen, representing 7.6% of the class.
• Averill Master Fund, Ltd. directly holds 4,137,797 shares, representing 6.6% of the class, with these shares indirectly beneficially owned by Suvretta Capital Management, LLC and Aaron Cowen.
• The reported ownership includes shares that may be acquired through the exercise of pre-funded warrants with a nominal exercise price of $0.00001 per share.
• Exercise of these pre-funded warrants is subject to a limitation, preventing the holders from beneficially owning more than 9.99% of the outstanding Common Stock, though this limit can be increased to 19.99% with a 61-day notice period.

Sentiment

Score: 6

Explanation: The filing indicates a significant and potentially increasing stake by a group of investors, which can be viewed as a positive signal of confidence in the company, although it is a routine disclosure.

Positives

• Increased beneficial ownership by institutional investors and a key individual (Aaron Cowen) may signal confidence in Aura Biosciences, Inc.
• The inclusion of pre-funded warrants provides a mechanism for future equity conversion at a very low exercise price, potentially indicating a favorable entry point for the investors.

Negatives

• The limitation on warrant exercise (9.99% initial cap, 19.99% with 61-day notice) means the full potential ownership from warrants is not immediately realizable.

Risks

• Beneficial ownership percentage could fluctuate based on the exercise of pre-funded warrants and changes in outstanding common stock, subject to stated limitations.
• Reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest, which is a standard legal disclaimer but highlights the indirect nature of some ownership.

Future Outlook

N/A

Management Comments

• The undersigned agree that this Schedule 13G Amendment No. 1 dated August 13, 2025 relating to the Common Stock, par value $0.00001 per share, of Aura Biosciences, Inc. shall be filed on behalf of the undersigned.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
• Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

This filing reflects a significant ownership stake by an investment firm and its affiliates in a biotechnology company, which is common for institutional investors seeking exposure to growth sectors like biotech.

Comparison to Industry Standards

• Institutional ownership stakes of 5% or more are common for active investment funds in publicly traded companies.
• The use of pre-funded warrants is a standard financing mechanism that allows investors to acquire equity while managing immediate ownership percentages and potential tax implications.
• The 9.99% beneficial ownership cap (and potential increase to 19.99%) is a common anti-takeover or passive investment threshold often seen in such agreements, allowing significant investment without triggering certain regulatory or corporate governance thresholds that apply to larger stakes (e.g., 20% or 25% thresholds for equity method accounting or control presumption).

Related Party Transactions

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen are filing as a group, indicating a related party relationship for the purpose of their investment in Aura Biosciences, Inc.
• Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability and signal investor confidence.
• Company Management: Awareness of a significant and potentially growing stake held by a specific investor group.

Next Steps

• The reporting persons may increase their beneficial ownership up to 19.99% by providing 61 days' written notice to the Issuer regarding the exercise of pre-funded warrants.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not contain sufficient information regarding the company's financial performance, strategic direction, or market valuation to warrant a 'buy' or 'sell' recommendation. It primarily indicates an investor group's continued interest and significant stake.

Keywords

Aura Biosciences, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Schedule 13G, beneficial ownership, common stock, pre-funded warrants, institutional investment, biotech, pharmaceuticals